Skip Navigation

For U.S. Healthcare Professionals

Patient.

Mechanism
of Action

Made for
Selectivity

Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.1-7

Healthcare professional.

For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.

ENTYVIO WAS MADE FOR SELECTIVITY1‑6

Entyvio helps address inflammation where it occurs—the gut1

Ulcerative colitis and Crohn's disease cause chronic inflammation of the gut, and infiltrating T‑lymphocytes cross the endothelium into the inflamed GI tissue.8 Entyvio is the first and only gut‑selective biologic to focus its action on an inflammatory pathway in the gut.1-6

THE ONLY GUT-SELECTIVE BIOLOGIC FOR UC AND CD1,5

  • Lymphocytes migrate into the GI tissue. An increased number of infiltrating lymphocytes and other inflammatory cells in the gut is one of the contributors to the inflammatory response.1,8

    Inflammation in the gut due to excess lymphocyte migration in UC and Crohn's disease.
    Artist rendition
GI = gastrointestinal; MAdCAM-1 = mucosal addressin cell adhesion molecule‑1.
Inflammation due to excess lymphocyte migration
Artist rendition

Crohn's Disease Data

SEE RESULTS IN CD

Entyvio Safety Profile

VIEW SAFETY PROFILE

References:

  1. Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.
  2. Fedyk E, Wyant T, Yang LL, et al. Inflamm Bowel Dis. 2012;18(11):2107-2119.
  3. Soler D, Chapman T, Yang LL, et al. J Pharmacol Exp Ther. 2009;330(3):864-875.
  4. Wyant T, Leach T, Sankoh S, et al. Gut. 2015;64(1):77-83.
  5. Wyant T, Fedyk E, Abhyankar B. J Crohns Colitis. 2016;10(12):1437-1444.
  6. Milch C, Wyant T, Xu J, et al. J Neuroimmunol. 2013;264:123-126.
  7. Briskin M, Winsor-Hines D, Shyjan A, et al. Am J Pathol. 1997;151(1):97-110.
  8. Xavier RJ, Podolsky DK. Nature. 2007;448(7152):427-434.